While TRF2 overexpression increased the quantity of CD31+ CD45− endothelial cells within the tumor bed (Figure 3H; Figure S4E), no difference was detected between empty vector or TRF2-overexpressing tumors after treatment with either drug. The gene discussed is PTPRC; the disease is neoplasm.